scholarly journals CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans

2010 ◽  
Vol 12 (2) ◽  
pp. 176-183 ◽  
Author(s):  
A LLerena ◽  
P Dorado ◽  
R Ramírez ◽  
I González ◽  
M Álvarez ◽  
...  
Keyword(s):  
Cyp2d6 Genotype ◽  
Debrisoquine Hydroxylation

scholarly journals CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice

2021 ◽  
Author(s):  
Daniel Carranza-Leon ◽  
Alyson L. Dickson ◽  
Andrea Gaedigk ◽  
C. Michael Stein ◽  
Cecilia P. Chung
Keyword(s):  
Clinical Practice ◽  
Real World ◽  
Analgesic Effect ◽  
Cyp2d6 Genotype

scholarly journals Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Andrea DeCensi ◽  
Harriet Johansson ◽  
Thomas Helland ◽  
Matteo Puntoni ◽  
Debora Macis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Low Dose ◽  
Cancer Recurrence ◽  
Phase Iii ◽  
Cyp2d6 Genotype ◽  
Phase Iii Trial ◽  
Reactive Protein ◽  
Non Invasive ◽  
Tamoxifen Metabolites ◽  
Dose Trial

AbstractLow-dose tamoxifen halves recurrence in non-invasive breast cancer without significant adverse events. Some adjuvant trials with tamoxifen 20 mg/day had shown an association between low endoxifen levels (9–16 nM) and recurrence, but no association with CYP2D6 was shown in the NSABP P1 and P2 prevention trials. We studied the association of CYP2D6 genotype and tamoxifen metabolites with tumor biomarkers and recurrence in a randomized phase III trial of low-dose tamoxifen. Median (IQR) endoxifen levels at year 1 were 8.4 (5.3–11.4) in patients who recurred vs 7.5 (5.1–10.2) in those who did not recur (p = 0.60). Tamoxifen and metabolites significantly decreased C-reactive protein (CRP, p < 0.05), and a CRP increase after 3 years was associated with higher risk of recurrence (HR = 4.37, 95% CI, 1.14–16.73, P = 0.03). In conclusion, endoxifen is below 9 nM in most subjects treated with 5 mg/day despite strong efficacy and there is no association with recurrence, suggesting that the reason for tamoxifen failure is not poor drug metabolism. Trial registration: ClinicalTrials.gov, Identifier: NCT01357772.

Biochemical and clinical effects of amiflamine-determined by the debrisoquine hydroxylation phenotype?

1987 ◽  
Vol 41 (2) ◽  
pp. 141-148
Author(s):  
Anna Åberg-Wistedt ◽  
Maia Alvariza ◽  
Leif Bertilsson ◽  
Thorbjörn Nerdrum ◽  
Conny Nordin ◽  
...  
Keyword(s):  
Clinical Effects ◽  
Debrisoquine Hydroxylation

scholarly journals Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia

2006 ◽  
Vol 63 (2) ◽  
pp. 217-218
Author(s):  
Kosuke Doki ◽  
Masato Homma ◽  
Keisuke Kuga ◽  
Kazutomi Kusano ◽  
Shigeyuki Watanabe ◽  
...  
Keyword(s):  
Japanese Patients ◽  
Cyp2d6 Genotype ◽  
Supraventricular Tachyarrhythmia

GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: effects on P53, ras and gsp

1995 ◽  
Vol 16 (7) ◽  
pp. 1643-1645 ◽  
Author(s):  
Christopher W. Perrett ◽  
Richard N. Clayton ◽  
Matteo Pistorello ◽  
Marco Boscaro ◽  
Massimilio Scanarini ◽  
...  
Keyword(s):  
Cyp2d6 Genotype ◽  
Pituitary Tumours ◽  
Genotype Frequencies

CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6–serotonin–dopamine crosstalk revisited

2007 ◽  
Vol 17 (5) ◽  
pp. 339-347 ◽  
Author(s):  
Vural Ozdemir ◽  
Leif Bertilsson ◽  
Jun Miura ◽  
Erin Carpenter ◽  
Christopher Reist ◽  
...  
Keyword(s):  
Cyp2d6 Genotype ◽  
Tissue Sensitivity
Sign in / Sign up

Export Citation Format

Share Document